Aripiprazole (Abilify Maintena) vs Brexpiprazole (Rexulti)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2/D3 and serotonin 5-HT1A receptor · full Schizophrenia pipeline

Aripiprazole (Abilify Maintena)

Marketed by Otsuka Holdings and partners

Approved in Schizophreniasmall molecule
Reliable signal

NCT00706654 · Phase 3 · completed

This was a randomized, double-blind, active-controlled trial with 662 randomized maintenance-phase participants, including 265 assigned to depot 300/400 mg and 266 to oral aripiprazole. The primary clinical relapse endpoint was met: depot treatment was non-inferior to oral aripiprazole, with a difference of -0.64 percentage points and a 95% confidence interval of -5.26 to 3.99, below the prespecified 11.5% margin.

Reported efficacy

Mean change from baseline to endpoint(10th week)in PANSS Total Score. (1st,2nd,4th,6th,8th,10th,12th week): LS mean change from baseline to Week 10 in PANSS Total Score: -33.6 (aripiprazole once-monthly, AOM) vs -34.8 (oral aripiprazole); difference -1.2 (95% CI: -4.1, 1.7), within the pre-defined non-inferiority margin (met)

Result source: NCT03172871

Brexpiprazole (Rexulti)

Marketed by Otsuka Holdings and partners

Approved in Schizophreniasmall molecule
Partial signal

NCT01393613 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial in 674 patients with acute schizophrenia, using a validated symptom-severity scale (PANSS) as the primary measure. The pooled comparison of the two higher doses against placebo reached statistical significance (p=0.0093), and the 4 mg dose was significant on its own (p=0.0022), but the 1 mg and 2 mg doses individually did not separate from placebo, so the result was only partially met.

Next expected readout: August 2027 · NCT07742280 (registry estimate)

Reported efficacy

Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score: Change from baseline to Week 6 in PANSS total score: brexpiprazole -22.8 (SE 1.5) vs placebo -17.4 (SE 1.6); least-squares mean difference -5.33, 95% CI -9.55 to -1.10, p=0.014 (met)

Result source: NCT03198078

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAripiprazole (Abilify Maintena)Brexpiprazole (Rexulti)
PANSS total, change-21.5 vs -10.3−11.2 vs placebo400/300 mg · wk 6 · n 162NCT01663532
6 other results
  • -19 vs -9.8 400/300 mg · wk 4 · n 162 · Phase 3 · primary NCT01663532
  • -23.7 vs -9.7 400/300 mg · wk 8 · n 162 · Phase 3 · primary NCT01663532
  • -15.2 vs -8.3 400/300 mg · wk 2 · n 162 · Phase 3 · primary NCT01663532
  • -26.8 vs -11.7 400/300 mg · wk 10 · n 162 · Phase 3 · primary NCT01663532
  • -8.9 vs -5 400/300 mg · wk 1 · n 162 · Phase 3 · primary NCT01663532
  • -33.6 vs -34.8 wk 10 · Phase 3 · primary NCT03172871
-16.6 vs -13.5−3.1 vs placebo2 mg · wk 6 · n 179NCT01393613
71 other results
  • -20.7 vs -12.0 2 mg · wk 6 · n 132 · Phase 3 · primary NCT01396421
  • -14.9 vs -7.6 2 mg · wk 6 · n 113 · Phase 2/3 · primary NCT01451164
  • -14.1 vs -11.9 2 mg · wk 5 · n 179 · Phase 3 · primary NCT01393613
  • -14.0 vs -6.6 2 mg · wk 5 · n 113 · Phase 2/3 · primary NCT01451164
  • -13.1 vs -11.1 2 mg · wk 4 · n 179 · Phase 3 · primary NCT01393613
  • -12.3 vs -5.7 2 mg · wk 4 · n 113 · Phase 2/3 · primary NCT01451164
  • -10.7 vs -8.9 2 mg · wk 3 · n 179 · Phase 3 · primary NCT01393613
  • -11 vs -6 2 mg · wk 3 · n 113 · Phase 2/3 · primary NCT01451164
  • -8.7 vs -6.6 2 mg · wk 2 · n 179 · Phase 3 · primary NCT01393613
  • -7.9 vs -4.5 2 mg · wk 2 · n 113 · Phase 2/3 · primary NCT01451164
  • -4.3 vs -3.5 2 mg · wk 1 · n 179 · Phase 3 · primary NCT01393613
  • -4.6 vs -3.1 2 mg · wk 1 · n 113 · Phase 2/3 · primary NCT01451164
  • -20 vs -13.5 4 mg · wk 6 · n 181 · Phase 3 · primary NCT01393613
  • -19.6 vs -12.0 4 mg · wk 6 · n 134 · Phase 3 · primary NCT01396421
  • -11.5 vs -7.6 4 mg · wk 6 · n 109 · Phase 2/3 · primary NCT01451164
  • -17.3 vs -11.9 4 mg · wk 5 · n 181 · Phase 3 · primary NCT01393613
  • -11.1 vs -6.6 4 mg · wk 5 · n 109 · Phase 2/3 · primary NCT01451164
  • -15.6 vs -11.1 4 mg · wk 4 · n 181 · Phase 3 · primary NCT01393613
  • -11.2 vs -5.7 4 mg · wk 4 · n 109 · Phase 2/3 · primary NCT01451164
  • -12.6 vs -8.9 4 mg · wk 3 · n 181 · Phase 3 · primary NCT01393613
  • -9.4 vs -6 4 mg · wk 3 · n 109 · Phase 2/3 · primary NCT01451164
  • -8.4 vs -6.6 4 mg · wk 2 · n 181 · Phase 3 · primary NCT01393613
  • -6.8 vs -4.5 4 mg · wk 2 · n 109 · Phase 2/3 · primary NCT01451164
  • -5.6 vs -3.5 4 mg · wk 1 · n 181 · Phase 3 · primary NCT01393613
  • -3.4 vs -3.1 4 mg · wk 1 · n 109 · Phase 2/3 · primary NCT01451164
  • -16.9 vs -13.5 1 mg · wk 6 · n 117 · Phase 3 · primary NCT01393613
  • -8.3 vs -7.6 1 mg · wk 6 · n 112 · Phase 2/3 · primary NCT01451164
  • -14.5 vs -11.9 1 mg · wk 5 · n 117 · Phase 3 · primary NCT01393613
  • -8.1 vs -6.6 1 mg · wk 5 · n 112 · Phase 2/3 · primary NCT01451164
  • -14.0 vs -11.1 1 mg · wk 4 · n 117 · Phase 3 · primary NCT01393613
  • -8.4 vs -5.7 1 mg · wk 4 · n 112 · Phase 2/3 · primary NCT01451164
  • -11.6 vs -8.9 1 mg · wk 3 · n 117 · Phase 3 · primary NCT01393613
  • -6.9 vs -6 1 mg · wk 3 · n 112 · Phase 2/3 · primary NCT01451164
  • -7.6 vs -6.6 1 mg · wk 2 · n 117 · Phase 3 · primary NCT01393613
  • -5.1 vs -4.5 1 mg · wk 2 · n 112 · Phase 2/3 · primary NCT01451164
  • -3.3 vs -3.5 1 mg · wk 1 · n 117 · Phase 3 · primary NCT01393613
  • -2.7 vs -3.1 1 mg · wk 1 · n 112 · Phase 2/3 · primary NCT01451164
  • -14.9 vs -12.0 0.25 mg · wk 6 · n 62 · Phase 3 · primary NCT01396421
  • -22.8 vs -17.4 wk 6 · n 110 · Phase 3 · primary NCT03198078
  • -20 vs -15.9 wk 6 · n 150 · Phase 3 · primary NCT01810380
  • -22.9 vs -19.4 wk 6 · n 64 · Phase 3 · primary NCT02054702
  • -17.9 vs -10.8 2 mg · wk 5 · n 180 · Phase 3 · secondary NCT01396421
  • -14.1 vs -8.9 2 mg · wk 4 · n 180 · Phase 3 · secondary NCT01396421
  • -11.1 vs -7.6 2 mg · wk 3 · n 180 · Phase 3 · secondary NCT01396421
  • -8.9 vs -5.1 2 mg · wk 2 · n 180 · Phase 3 · secondary NCT01396421
  • -4.9 vs -2.9 2 mg · wk 1 · n 180 · Phase 3 · secondary NCT01396421
  • -18.6 vs -10.8 4 mg · wk 5 · n 178 · Phase 3 · secondary NCT01396421
  • -16.5 vs -8.9 4 mg · wk 4 · n 178 · Phase 3 · secondary NCT01396421
  • -12.8 vs -7.6 4 mg · wk 3 · n 178 · Phase 3 · secondary NCT01396421
  • -9.5 vs -5.1 4 mg · wk 2 · n 178 · Phase 3 · secondary NCT01396421
  • -4.4 vs -2.9 4 mg · wk 1 · n 178 · Phase 3 · secondary NCT01396421
  • -11.9 vs -10.8 0.25 mg · wk 5 · n 87 · Phase 3 · secondary NCT01396421
  • -8.9 vs -8.9 0.25 mg · wk 4 · n 87 · Phase 3 · secondary NCT01396421
  • -5.7 vs -7.6 0.25 mg · wk 3 · n 87 · Phase 3 · secondary NCT01396421
  • -3.3 vs -5.1 0.25 mg · wk 2 · n 87 · Phase 3 · secondary NCT01396421
  • -2.5 vs -2.9 0.25 mg · wk 1 · n 87 · Phase 3 · secondary NCT01396421
  • 0.8 vs 4.1 wk 6 · n 96 · Phase 3 · secondary NCT01668797
  • 0.5 vs 3.6 wk 6 · n 96 · Phase 3 · secondary NCT01668797
  • 0.8 vs 6.2 wk 12 · n 96 · Phase 3 · secondary NCT01668797
  • 1.6 vs 6.6 wk 12 · n 96 · Phase 3 · secondary NCT01668797
  • -1.9 vs 2.9 wk 24 · n 96 · Phase 3 · secondary NCT01668797
  • 1.6 vs 9.2 wk 24 · n 96 · Phase 3 · secondary NCT01668797
  • -2.7 vs 3.3 wk 36 · n 96 · Phase 3 · secondary NCT01668797
  • 2.5 vs 10.5 wk 36 · n 96 · Phase 3 · secondary NCT01668797
  • 0.6 vs 6.9 wk 52 · n 96 · Phase 3 · secondary NCT01668797
  • 3.3 vs 11.2 wk 52 · n 96 · Phase 3 · secondary NCT01668797
  • -9.8 vs -14.4 0.25 mg · wk 6 · n 41 · Phase 2 · primary NCT00905307
  • -18.7 vs -14.4 Low-dose · wk 6 · n 88 · Phase 2 · primary NCT00905307
  • -16.2 vs -14.4 Mid-dose · wk 6 · n 90 · Phase 2 · primary NCT00905307
  • -18.3 vs -14.4 High-dose · wk 6 · n 92 · Phase 2 · primary NCT00905307
  • -3.7 vs -0.3 wk 12 · n 21 · Phase 4 · secondary NCT03526354
CGI-S, change-1.2 vs -0.5−0.7 vs placebo400/300 mg · wk 6 · n 162NCT01663532
6 other results
  • -1 vs -0.4 400/300 mg · wk 4 · n 162 · Phase 3 · secondary NCT01663532
  • -1.3 vs -0.6 400/300 mg · wk 8 · n 162 · Phase 3 · secondary NCT01663532
  • -0.8 vs -0.4 400/300 mg · wk 2 · n 162 · Phase 3 · secondary NCT01663532
  • -1.4 vs -0.6 400/300 mg · wk 10 · n 162 · Phase 3 · secondary NCT01663532
  • -0.4 vs -0.2 400/300 mg · wk 1 · n 162 · Phase 3 · secondary NCT01663532
  • -0.8 vs -0.5 wk 28 · n 136 · Phase 3 · secondary NCT01795547
-1.0 vs -0.8−0.2 vs placebo2 mg · wk 6 · n 180NCT01393613
71 other results
  • -1.1 vs -0.8 2 mg · wk 6 · n 124 · Phase 3 · secondary NCT01396421
  • -0.8 vs -0.6 2 mg · wk 6 · n 113 · Phase 2/3 · secondary NCT01451164
  • -0.8 vs -0.7 2 mg · wk 5 · n 180 · Phase 3 · secondary NCT01393613
  • -1.0 vs -0.7 2 mg · wk 5 · n 181 · Phase 3 · secondary NCT01396421
  • -0.8 vs -0.5 2 mg · wk 5 · n 113 · Phase 2/3 · secondary NCT01451164
  • -0.7 vs -0.6 2 mg · wk 4 · n 180 · Phase 3 · secondary NCT01393613
  • -0.7 vs -0.5 2 mg · wk 4 · n 181 · Phase 3 · secondary NCT01396421
  • -0.6 vs -0.4 2 mg · wk 4 · n 113 · Phase 2/3 · secondary NCT01451164
  • -0.6 vs -0.4 2 mg · wk 3 · n 180 · Phase 3 · secondary NCT01393613
  • -0.6 vs -0.5 2 mg · wk 3 · n 181 · Phase 3 · secondary NCT01396421
  • -0.5 vs -0.4 2 mg · wk 3 · n 113 · Phase 2/3 · secondary NCT01451164
  • -0.4 vs -0.4 2 mg · wk 2 · n 180 · Phase 3 · secondary NCT01393613
  • -0.4 vs -0.3 2 mg · wk 2 · n 181 · Phase 3 · secondary NCT01396421
  • -0.4 vs -0.3 2 mg · wk 2 · n 113 · Phase 2/3 · secondary NCT01451164
  • -0.2 vs -0.1 2 mg · wk 1 · n 180 · Phase 3 · secondary NCT01393613
  • -0.2 vs -0.1 2 mg · wk 1 · n 181 · Phase 3 · secondary NCT01396421
  • -0.2 vs -0.1 2 mg · wk 1 · n 113 · Phase 2/3 · secondary NCT01451164
  • -1.2 vs -0.8 4 mg · wk 6 · n 183 · Phase 3 · secondary NCT01393613
  • -1.2 vs -0.8 4 mg · wk 6 · n 121 · Phase 3 · secondary NCT01396421
  • -0.6 vs -0.6 4 mg · wk 6 · n 109 · Phase 2/3 · secondary NCT01451164
  • -1.0 vs -0.7 4 mg · wk 5 · n 183 · Phase 3 · secondary NCT01393613
  • -1.1 vs -0.7 4 mg · wk 5 · n 178 · Phase 3 · secondary NCT01396421
  • -0.6 vs -0.5 4 mg · wk 5 · n 109 · Phase 2/3 · secondary NCT01451164
  • -0.8 vs -0.6 4 mg · wk 4 · n 183 · Phase 3 · secondary NCT01393613
  • -1.0 vs -0.5 4 mg · wk 4 · n 178 · Phase 3 · secondary NCT01396421
  • -0.5 vs -0.4 4 mg · wk 4 · n 109 · Phase 2/3 · secondary NCT01451164
  • -0.7 vs -0.4 4 mg · wk 3 · n 183 · Phase 3 · secondary NCT01393613
  • -0.7 vs -0.5 4 mg · wk 3 · n 178 · Phase 3 · secondary NCT01396421
  • -0.5 vs -0.4 4 mg · wk 3 · n 109 · Phase 2/3 · secondary NCT01451164
  • -0.4 vs -0.4 4 mg · wk 2 · n 183 · Phase 3 · secondary NCT01393613
  • -0.5 vs -0.3 4 mg · wk 2 · n 178 · Phase 3 · secondary NCT01396421
  • -0.3 vs -0.3 4 mg · wk 2 · n 109 · Phase 2/3 · secondary NCT01451164
  • -0.2 vs -0.1 4 mg · wk 1 · n 183 · Phase 3 · secondary NCT01393613
  • -0.2 vs -0.1 4 mg · wk 1 · n 178 · Phase 3 · secondary NCT01396421
  • -0.1 vs -0.1 4 mg · wk 1 · n 109 · Phase 2/3 · secondary NCT01451164
  • -0.9 vs -0.8 1 mg · wk 6 · n 120 · Phase 3 · secondary NCT01393613
  • -0.5 vs -0.6 1 mg · wk 6 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.8 vs -0.7 1 mg · wk 5 · n 120 · Phase 3 · secondary NCT01393613
  • -0.5 vs -0.5 1 mg · wk 5 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.7 vs -0.6 1 mg · wk 4 · n 120 · Phase 3 · secondary NCT01393613
  • -0.5 vs -0.4 1 mg · wk 4 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.6 vs -0.4 1 mg · wk 3 · n 120 · Phase 3 · secondary NCT01393613
  • -0.4 vs -0.4 1 mg · wk 3 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.3 vs -0.4 1 mg · wk 2 · n 120 · Phase 3 · secondary NCT01393613
  • -0.3 vs -0.3 1 mg · wk 2 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.1 vs -0.1 1 mg · wk 1 · n 120 · Phase 3 · secondary NCT01393613
  • -0.1 vs -0.1 1 mg · wk 1 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.8 vs -0.8 0.25 mg · wk 6 · n 56 · Phase 3 · secondary NCT01396421
  • -0.7 vs -0.7 0.25 mg · wk 5 · n 89 · Phase 3 · secondary NCT01396421
  • -0.6 vs -0.5 0.25 mg · wk 4 · n 89 · Phase 3 · secondary NCT01396421
  • -0.3 vs -0.5 0.25 mg · wk 3 · n 89 · Phase 3 · secondary NCT01396421
  • -0.2 vs -0.3 0.25 mg · wk 2 · n 89 · Phase 3 · secondary NCT01396421
  • -0.1 vs -0.1 0.25 mg · wk 1 · n 89 · Phase 3 · secondary NCT01396421
  • -0.9 vs -0.8 wk 6 · n 110 · Phase 3 · secondary NCT03198078
  • -0.0 vs 0.3 wk 6 · n 96 · Phase 3 · secondary NCT01668797
  • -0.1 vs 0.2 wk 6 · n 96 · Phase 3 · secondary NCT01668797
  • -1.2 vs -0.9 wk 6 · n 150 · Phase 3 · secondary NCT01810380
  • -0.0 vs 0.4 wk 12 · n 96 · Phase 3 · secondary NCT01668797
  • -0.0 vs 0.3 wk 12 · n 96 · Phase 3 · secondary NCT01668797
  • -0.2 vs 0.2 wk 24 · n 96 · Phase 3 · secondary NCT01668797
  • -0.0 vs 0.5 wk 24 · n 96 · Phase 3 · secondary NCT01668797
  • -0.3 vs 0.3 wk 36 · n 96 · Phase 3 · secondary NCT01668797
  • 0 vs 0.6 wk 36 · n 96 · Phase 3 · secondary NCT01668797
  • -0.2 vs 0.3 wk 52 · n 96 · Phase 3 · secondary NCT01668797
  • 0.0 vs 0.6 wk 52 · n 96 · Phase 3 · secondary NCT01668797
  • -1.6 vs -1.3 wk 6 · n 64 · Phase 3 · secondary NCT02054702
  • -0.4 vs -0.8 0.25 mg · wk 6 · n 41 · Phase 2 · secondary NCT00905307
  • -1.0 vs -0.8 Low-dose · wk 6 · n 88 · Phase 2 · secondary NCT00905307
  • -0.9 vs -0.8 Mid-dose · wk 6 · n 90 · Phase 2 · secondary NCT00905307
  • -1.1 vs -0.8 High-dose · wk 6 · n 92 · Phase 2 · secondary NCT00905307
  • -0.3 vs -0.1 wk 12 · n 21 · Phase 4 · secondary NCT03526354
PANSS response37% vs 14.3%+22.7 vs placebo400/300 mg · wk 10 · n 162NCT0166353238.5% vs 31.7%+6.8 vs placebo2 mg · wk 6 · n 179NCT01393613
8 other results
  • 49.7% vs 31.7% 4 mg · wk 6 · n 181 · Phase 3 · secondary NCT01393613
  • 43.6% vs 31.7% 1 mg · wk 6 · n 117 · Phase 3 · secondary NCT01393613
  • 43.6% vs 28.2% wk 6 · n 110 · Phase 3 · secondary NCT03198078
  • 48.7% vs 32.1% wk 6 · n 150 · Phase 3 · secondary NCT01810380
  • 40.5% vs 49.5% 0.25 mg · wk 6 · n 42 · Phase 2 · secondary NCT00905307
  • 57.3% vs 49.5% Low-dose · wk 6 · n 89 · Phase 2 · secondary NCT00905307
  • 46.7% vs 49.5% Mid-dose · wk 6 · n 90 · Phase 2 · secondary NCT00905307
  • 51.6% vs 49.5% High-dose · wk 6 · n 93 · Phase 2 · secondary NCT00905307
PSP, change12.3 vs 5.2+7.1 vs placebo400/300 mg · wk 10 · n 139NCT0166353210.5 vs 8.5+2 vs placebo2 mg · wk 6 · n 170NCT01393613
17 other results
  • 13.2 vs 10.3 2 mg · wk 6 · n 122 · Phase 3 · secondary NCT01396421
  • 6.8 vs 5.8 2 mg · wk 3 · n 170 · Phase 3 · secondary NCT01393613
  • 13.1 vs 8.5 4 mg · wk 6 · n 174 · Phase 3 · secondary NCT01393613
  • 12.7 vs 10.3 4 mg · wk 6 · n 121 · Phase 3 · secondary NCT01396421
  • 7.1 vs 5.8 4 mg · wk 3 · n 174 · Phase 3 · secondary NCT01393613
  • 11.7 vs 8.5 1 mg · wk 6 · n 105 · Phase 3 · secondary NCT01393613
  • 7.0 vs 5.8 1 mg · wk 3 · n 105 · Phase 3 · secondary NCT01393613
  • 11.8 vs 10.3 0.25 mg · wk 6 · n 55 · Phase 3 · secondary NCT01396421
  • 18.6 vs 12.6 wk 52 · n 96 · Phase 3 · secondary NCT01668797
  • 15.1 vs 10.3 wk 52 · n 94 · Phase 3 · secondary NCT01668797
  • 18.9 vs 17.8 wk 24 · n 96 · Phase 3 · secondary NCT01668797
  • 15.2 vs 11.4 wk 24 · n 94 · Phase 3 · secondary NCT01668797
  • 13 vs 9.4 wk 6 · n 133 · Phase 3 · secondary NCT01810380
  • 4.5 vs 7.6 0.25 mg · wk 6 · n 39 · Phase 2 · secondary NCT00905307
  • 11.4 vs 7.6 Low-dose · wk 6 · n 86 · Phase 2 · secondary NCT00905307
  • 10.7 vs 7.6 Mid-dose · wk 6 · n 84 · Phase 2 · secondary NCT00905307
  • 12.2 vs 7.6 High-dose · wk 6 · n 90 · Phase 2 · secondary NCT00905307
Relapse (% of patients)10% vs 39.6%−29.6 vs placebowk 52 · n 269NCT0070578313.5% vs 38.5%−24.9 vs placebowk 52 · n 96NCT01668797

PANSS total, change

Aripiprazole (Abilify Maintena)
-21.5 vs -10.3−11.2 vs placebo400/300 mg · wk 6 · n 162NCT01663532
6 other results
  • -19 vs -9.8 400/300 mg · wk 4 · n 162 · Phase 3 · primary NCT01663532
  • -23.7 vs -9.7 400/300 mg · wk 8 · n 162 · Phase 3 · primary NCT01663532
  • -15.2 vs -8.3 400/300 mg · wk 2 · n 162 · Phase 3 · primary NCT01663532
  • -26.8 vs -11.7 400/300 mg · wk 10 · n 162 · Phase 3 · primary NCT01663532
  • -8.9 vs -5 400/300 mg · wk 1 · n 162 · Phase 3 · primary NCT01663532
  • -33.6 vs -34.8 wk 10 · Phase 3 · primary NCT03172871
Brexpiprazole (Rexulti)
-16.6 vs -13.5−3.1 vs placebo2 mg · wk 6 · n 179NCT01393613
71 other results
  • -20.7 vs -12.0 2 mg · wk 6 · n 132 · Phase 3 · primary NCT01396421
  • -14.9 vs -7.6 2 mg · wk 6 · n 113 · Phase 2/3 · primary NCT01451164
  • -14.1 vs -11.9 2 mg · wk 5 · n 179 · Phase 3 · primary NCT01393613
  • -14.0 vs -6.6 2 mg · wk 5 · n 113 · Phase 2/3 · primary NCT01451164
  • -13.1 vs -11.1 2 mg · wk 4 · n 179 · Phase 3 · primary NCT01393613
  • -12.3 vs -5.7 2 mg · wk 4 · n 113 · Phase 2/3 · primary NCT01451164
  • -10.7 vs -8.9 2 mg · wk 3 · n 179 · Phase 3 · primary NCT01393613
  • -11 vs -6 2 mg · wk 3 · n 113 · Phase 2/3 · primary NCT01451164
  • -8.7 vs -6.6 2 mg · wk 2 · n 179 · Phase 3 · primary NCT01393613
  • -7.9 vs -4.5 2 mg · wk 2 · n 113 · Phase 2/3 · primary NCT01451164
  • -4.3 vs -3.5 2 mg · wk 1 · n 179 · Phase 3 · primary NCT01393613
  • -4.6 vs -3.1 2 mg · wk 1 · n 113 · Phase 2/3 · primary NCT01451164
  • -20 vs -13.5 4 mg · wk 6 · n 181 · Phase 3 · primary NCT01393613
  • -19.6 vs -12.0 4 mg · wk 6 · n 134 · Phase 3 · primary NCT01396421
  • -11.5 vs -7.6 4 mg · wk 6 · n 109 · Phase 2/3 · primary NCT01451164
  • -17.3 vs -11.9 4 mg · wk 5 · n 181 · Phase 3 · primary NCT01393613
  • -11.1 vs -6.6 4 mg · wk 5 · n 109 · Phase 2/3 · primary NCT01451164
  • -15.6 vs -11.1 4 mg · wk 4 · n 181 · Phase 3 · primary NCT01393613
  • -11.2 vs -5.7 4 mg · wk 4 · n 109 · Phase 2/3 · primary NCT01451164
  • -12.6 vs -8.9 4 mg · wk 3 · n 181 · Phase 3 · primary NCT01393613
  • -9.4 vs -6 4 mg · wk 3 · n 109 · Phase 2/3 · primary NCT01451164
  • -8.4 vs -6.6 4 mg · wk 2 · n 181 · Phase 3 · primary NCT01393613
  • -6.8 vs -4.5 4 mg · wk 2 · n 109 · Phase 2/3 · primary NCT01451164
  • -5.6 vs -3.5 4 mg · wk 1 · n 181 · Phase 3 · primary NCT01393613
  • -3.4 vs -3.1 4 mg · wk 1 · n 109 · Phase 2/3 · primary NCT01451164
  • -16.9 vs -13.5 1 mg · wk 6 · n 117 · Phase 3 · primary NCT01393613
  • -8.3 vs -7.6 1 mg · wk 6 · n 112 · Phase 2/3 · primary NCT01451164
  • -14.5 vs -11.9 1 mg · wk 5 · n 117 · Phase 3 · primary NCT01393613
  • -8.1 vs -6.6 1 mg · wk 5 · n 112 · Phase 2/3 · primary NCT01451164
  • -14.0 vs -11.1 1 mg · wk 4 · n 117 · Phase 3 · primary NCT01393613
  • -8.4 vs -5.7 1 mg · wk 4 · n 112 · Phase 2/3 · primary NCT01451164
  • -11.6 vs -8.9 1 mg · wk 3 · n 117 · Phase 3 · primary NCT01393613
  • -6.9 vs -6 1 mg · wk 3 · n 112 · Phase 2/3 · primary NCT01451164
  • -7.6 vs -6.6 1 mg · wk 2 · n 117 · Phase 3 · primary NCT01393613
  • -5.1 vs -4.5 1 mg · wk 2 · n 112 · Phase 2/3 · primary NCT01451164
  • -3.3 vs -3.5 1 mg · wk 1 · n 117 · Phase 3 · primary NCT01393613
  • -2.7 vs -3.1 1 mg · wk 1 · n 112 · Phase 2/3 · primary NCT01451164
  • -14.9 vs -12.0 0.25 mg · wk 6 · n 62 · Phase 3 · primary NCT01396421
  • -22.8 vs -17.4 wk 6 · n 110 · Phase 3 · primary NCT03198078
  • -20 vs -15.9 wk 6 · n 150 · Phase 3 · primary NCT01810380
  • -22.9 vs -19.4 wk 6 · n 64 · Phase 3 · primary NCT02054702
  • -17.9 vs -10.8 2 mg · wk 5 · n 180 · Phase 3 · secondary NCT01396421
  • -14.1 vs -8.9 2 mg · wk 4 · n 180 · Phase 3 · secondary NCT01396421
  • -11.1 vs -7.6 2 mg · wk 3 · n 180 · Phase 3 · secondary NCT01396421
  • -8.9 vs -5.1 2 mg · wk 2 · n 180 · Phase 3 · secondary NCT01396421
  • -4.9 vs -2.9 2 mg · wk 1 · n 180 · Phase 3 · secondary NCT01396421
  • -18.6 vs -10.8 4 mg · wk 5 · n 178 · Phase 3 · secondary NCT01396421
  • -16.5 vs -8.9 4 mg · wk 4 · n 178 · Phase 3 · secondary NCT01396421
  • -12.8 vs -7.6 4 mg · wk 3 · n 178 · Phase 3 · secondary NCT01396421
  • -9.5 vs -5.1 4 mg · wk 2 · n 178 · Phase 3 · secondary NCT01396421
  • -4.4 vs -2.9 4 mg · wk 1 · n 178 · Phase 3 · secondary NCT01396421
  • -11.9 vs -10.8 0.25 mg · wk 5 · n 87 · Phase 3 · secondary NCT01396421
  • -8.9 vs -8.9 0.25 mg · wk 4 · n 87 · Phase 3 · secondary NCT01396421
  • -5.7 vs -7.6 0.25 mg · wk 3 · n 87 · Phase 3 · secondary NCT01396421
  • -3.3 vs -5.1 0.25 mg · wk 2 · n 87 · Phase 3 · secondary NCT01396421
  • -2.5 vs -2.9 0.25 mg · wk 1 · n 87 · Phase 3 · secondary NCT01396421
  • 0.8 vs 4.1 wk 6 · n 96 · Phase 3 · secondary NCT01668797
  • 0.5 vs 3.6 wk 6 · n 96 · Phase 3 · secondary NCT01668797
  • 0.8 vs 6.2 wk 12 · n 96 · Phase 3 · secondary NCT01668797
  • 1.6 vs 6.6 wk 12 · n 96 · Phase 3 · secondary NCT01668797
  • -1.9 vs 2.9 wk 24 · n 96 · Phase 3 · secondary NCT01668797
  • 1.6 vs 9.2 wk 24 · n 96 · Phase 3 · secondary NCT01668797
  • -2.7 vs 3.3 wk 36 · n 96 · Phase 3 · secondary NCT01668797
  • 2.5 vs 10.5 wk 36 · n 96 · Phase 3 · secondary NCT01668797
  • 0.6 vs 6.9 wk 52 · n 96 · Phase 3 · secondary NCT01668797
  • 3.3 vs 11.2 wk 52 · n 96 · Phase 3 · secondary NCT01668797
  • -9.8 vs -14.4 0.25 mg · wk 6 · n 41 · Phase 2 · primary NCT00905307
  • -18.7 vs -14.4 Low-dose · wk 6 · n 88 · Phase 2 · primary NCT00905307
  • -16.2 vs -14.4 Mid-dose · wk 6 · n 90 · Phase 2 · primary NCT00905307
  • -18.3 vs -14.4 High-dose · wk 6 · n 92 · Phase 2 · primary NCT00905307
  • -3.7 vs -0.3 wk 12 · n 21 · Phase 4 · secondary NCT03526354

CGI-S, change

Aripiprazole (Abilify Maintena)
-1.2 vs -0.5−0.7 vs placebo400/300 mg · wk 6 · n 162NCT01663532
6 other results
  • -1 vs -0.4 400/300 mg · wk 4 · n 162 · Phase 3 · secondary NCT01663532
  • -1.3 vs -0.6 400/300 mg · wk 8 · n 162 · Phase 3 · secondary NCT01663532
  • -0.8 vs -0.4 400/300 mg · wk 2 · n 162 · Phase 3 · secondary NCT01663532
  • -1.4 vs -0.6 400/300 mg · wk 10 · n 162 · Phase 3 · secondary NCT01663532
  • -0.4 vs -0.2 400/300 mg · wk 1 · n 162 · Phase 3 · secondary NCT01663532
  • -0.8 vs -0.5 wk 28 · n 136 · Phase 3 · secondary NCT01795547
Brexpiprazole (Rexulti)
-1.0 vs -0.8−0.2 vs placebo2 mg · wk 6 · n 180NCT01393613
71 other results
  • -1.1 vs -0.8 2 mg · wk 6 · n 124 · Phase 3 · secondary NCT01396421
  • -0.8 vs -0.6 2 mg · wk 6 · n 113 · Phase 2/3 · secondary NCT01451164
  • -0.8 vs -0.7 2 mg · wk 5 · n 180 · Phase 3 · secondary NCT01393613
  • -1.0 vs -0.7 2 mg · wk 5 · n 181 · Phase 3 · secondary NCT01396421
  • -0.8 vs -0.5 2 mg · wk 5 · n 113 · Phase 2/3 · secondary NCT01451164
  • -0.7 vs -0.6 2 mg · wk 4 · n 180 · Phase 3 · secondary NCT01393613
  • -0.7 vs -0.5 2 mg · wk 4 · n 181 · Phase 3 · secondary NCT01396421
  • -0.6 vs -0.4 2 mg · wk 4 · n 113 · Phase 2/3 · secondary NCT01451164
  • -0.6 vs -0.4 2 mg · wk 3 · n 180 · Phase 3 · secondary NCT01393613
  • -0.6 vs -0.5 2 mg · wk 3 · n 181 · Phase 3 · secondary NCT01396421
  • -0.5 vs -0.4 2 mg · wk 3 · n 113 · Phase 2/3 · secondary NCT01451164
  • -0.4 vs -0.4 2 mg · wk 2 · n 180 · Phase 3 · secondary NCT01393613
  • -0.4 vs -0.3 2 mg · wk 2 · n 181 · Phase 3 · secondary NCT01396421
  • -0.4 vs -0.3 2 mg · wk 2 · n 113 · Phase 2/3 · secondary NCT01451164
  • -0.2 vs -0.1 2 mg · wk 1 · n 180 · Phase 3 · secondary NCT01393613
  • -0.2 vs -0.1 2 mg · wk 1 · n 181 · Phase 3 · secondary NCT01396421
  • -0.2 vs -0.1 2 mg · wk 1 · n 113 · Phase 2/3 · secondary NCT01451164
  • -1.2 vs -0.8 4 mg · wk 6 · n 183 · Phase 3 · secondary NCT01393613
  • -1.2 vs -0.8 4 mg · wk 6 · n 121 · Phase 3 · secondary NCT01396421
  • -0.6 vs -0.6 4 mg · wk 6 · n 109 · Phase 2/3 · secondary NCT01451164
  • -1.0 vs -0.7 4 mg · wk 5 · n 183 · Phase 3 · secondary NCT01393613
  • -1.1 vs -0.7 4 mg · wk 5 · n 178 · Phase 3 · secondary NCT01396421
  • -0.6 vs -0.5 4 mg · wk 5 · n 109 · Phase 2/3 · secondary NCT01451164
  • -0.8 vs -0.6 4 mg · wk 4 · n 183 · Phase 3 · secondary NCT01393613
  • -1.0 vs -0.5 4 mg · wk 4 · n 178 · Phase 3 · secondary NCT01396421
  • -0.5 vs -0.4 4 mg · wk 4 · n 109 · Phase 2/3 · secondary NCT01451164
  • -0.7 vs -0.4 4 mg · wk 3 · n 183 · Phase 3 · secondary NCT01393613
  • -0.7 vs -0.5 4 mg · wk 3 · n 178 · Phase 3 · secondary NCT01396421
  • -0.5 vs -0.4 4 mg · wk 3 · n 109 · Phase 2/3 · secondary NCT01451164
  • -0.4 vs -0.4 4 mg · wk 2 · n 183 · Phase 3 · secondary NCT01393613
  • -0.5 vs -0.3 4 mg · wk 2 · n 178 · Phase 3 · secondary NCT01396421
  • -0.3 vs -0.3 4 mg · wk 2 · n 109 · Phase 2/3 · secondary NCT01451164
  • -0.2 vs -0.1 4 mg · wk 1 · n 183 · Phase 3 · secondary NCT01393613
  • -0.2 vs -0.1 4 mg · wk 1 · n 178 · Phase 3 · secondary NCT01396421
  • -0.1 vs -0.1 4 mg · wk 1 · n 109 · Phase 2/3 · secondary NCT01451164
  • -0.9 vs -0.8 1 mg · wk 6 · n 120 · Phase 3 · secondary NCT01393613
  • -0.5 vs -0.6 1 mg · wk 6 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.8 vs -0.7 1 mg · wk 5 · n 120 · Phase 3 · secondary NCT01393613
  • -0.5 vs -0.5 1 mg · wk 5 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.7 vs -0.6 1 mg · wk 4 · n 120 · Phase 3 · secondary NCT01393613
  • -0.5 vs -0.4 1 mg · wk 4 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.6 vs -0.4 1 mg · wk 3 · n 120 · Phase 3 · secondary NCT01393613
  • -0.4 vs -0.4 1 mg · wk 3 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.3 vs -0.4 1 mg · wk 2 · n 120 · Phase 3 · secondary NCT01393613
  • -0.3 vs -0.3 1 mg · wk 2 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.1 vs -0.1 1 mg · wk 1 · n 120 · Phase 3 · secondary NCT01393613
  • -0.1 vs -0.1 1 mg · wk 1 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.8 vs -0.8 0.25 mg · wk 6 · n 56 · Phase 3 · secondary NCT01396421
  • -0.7 vs -0.7 0.25 mg · wk 5 · n 89 · Phase 3 · secondary NCT01396421
  • -0.6 vs -0.5 0.25 mg · wk 4 · n 89 · Phase 3 · secondary NCT01396421
  • -0.3 vs -0.5 0.25 mg · wk 3 · n 89 · Phase 3 · secondary NCT01396421
  • -0.2 vs -0.3 0.25 mg · wk 2 · n 89 · Phase 3 · secondary NCT01396421
  • -0.1 vs -0.1 0.25 mg · wk 1 · n 89 · Phase 3 · secondary NCT01396421
  • -0.9 vs -0.8 wk 6 · n 110 · Phase 3 · secondary NCT03198078
  • -0.0 vs 0.3 wk 6 · n 96 · Phase 3 · secondary NCT01668797
  • -0.1 vs 0.2 wk 6 · n 96 · Phase 3 · secondary NCT01668797
  • -1.2 vs -0.9 wk 6 · n 150 · Phase 3 · secondary NCT01810380
  • -0.0 vs 0.4 wk 12 · n 96 · Phase 3 · secondary NCT01668797
  • -0.0 vs 0.3 wk 12 · n 96 · Phase 3 · secondary NCT01668797
  • -0.2 vs 0.2 wk 24 · n 96 · Phase 3 · secondary NCT01668797
  • -0.0 vs 0.5 wk 24 · n 96 · Phase 3 · secondary NCT01668797
  • -0.3 vs 0.3 wk 36 · n 96 · Phase 3 · secondary NCT01668797
  • 0 vs 0.6 wk 36 · n 96 · Phase 3 · secondary NCT01668797
  • -0.2 vs 0.3 wk 52 · n 96 · Phase 3 · secondary NCT01668797
  • 0.0 vs 0.6 wk 52 · n 96 · Phase 3 · secondary NCT01668797
  • -1.6 vs -1.3 wk 6 · n 64 · Phase 3 · secondary NCT02054702
  • -0.4 vs -0.8 0.25 mg · wk 6 · n 41 · Phase 2 · secondary NCT00905307
  • -1.0 vs -0.8 Low-dose · wk 6 · n 88 · Phase 2 · secondary NCT00905307
  • -0.9 vs -0.8 Mid-dose · wk 6 · n 90 · Phase 2 · secondary NCT00905307
  • -1.1 vs -0.8 High-dose · wk 6 · n 92 · Phase 2 · secondary NCT00905307
  • -0.3 vs -0.1 wk 12 · n 21 · Phase 4 · secondary NCT03526354

PANSS response

Aripiprazole (Abilify Maintena)
37% vs 14.3%+22.7 vs placebo400/300 mg · wk 10 · n 162NCT01663532
Brexpiprazole (Rexulti)
38.5% vs 31.7%+6.8 vs placebo2 mg · wk 6 · n 179NCT01393613
8 other results
  • 49.7% vs 31.7% 4 mg · wk 6 · n 181 · Phase 3 · secondary NCT01393613
  • 43.6% vs 31.7% 1 mg · wk 6 · n 117 · Phase 3 · secondary NCT01393613
  • 43.6% vs 28.2% wk 6 · n 110 · Phase 3 · secondary NCT03198078
  • 48.7% vs 32.1% wk 6 · n 150 · Phase 3 · secondary NCT01810380
  • 40.5% vs 49.5% 0.25 mg · wk 6 · n 42 · Phase 2 · secondary NCT00905307
  • 57.3% vs 49.5% Low-dose · wk 6 · n 89 · Phase 2 · secondary NCT00905307
  • 46.7% vs 49.5% Mid-dose · wk 6 · n 90 · Phase 2 · secondary NCT00905307
  • 51.6% vs 49.5% High-dose · wk 6 · n 93 · Phase 2 · secondary NCT00905307

PSP, change

Aripiprazole (Abilify Maintena)
12.3 vs 5.2+7.1 vs placebo400/300 mg · wk 10 · n 139NCT01663532
Brexpiprazole (Rexulti)
10.5 vs 8.5+2 vs placebo2 mg · wk 6 · n 170NCT01393613
17 other results
  • 13.2 vs 10.3 2 mg · wk 6 · n 122 · Phase 3 · secondary NCT01396421
  • 6.8 vs 5.8 2 mg · wk 3 · n 170 · Phase 3 · secondary NCT01393613
  • 13.1 vs 8.5 4 mg · wk 6 · n 174 · Phase 3 · secondary NCT01393613
  • 12.7 vs 10.3 4 mg · wk 6 · n 121 · Phase 3 · secondary NCT01396421
  • 7.1 vs 5.8 4 mg · wk 3 · n 174 · Phase 3 · secondary NCT01393613
  • 11.7 vs 8.5 1 mg · wk 6 · n 105 · Phase 3 · secondary NCT01393613
  • 7.0 vs 5.8 1 mg · wk 3 · n 105 · Phase 3 · secondary NCT01393613
  • 11.8 vs 10.3 0.25 mg · wk 6 · n 55 · Phase 3 · secondary NCT01396421
  • 18.6 vs 12.6 wk 52 · n 96 · Phase 3 · secondary NCT01668797
  • 15.1 vs 10.3 wk 52 · n 94 · Phase 3 · secondary NCT01668797
  • 18.9 vs 17.8 wk 24 · n 96 · Phase 3 · secondary NCT01668797
  • 15.2 vs 11.4 wk 24 · n 94 · Phase 3 · secondary NCT01668797
  • 13 vs 9.4 wk 6 · n 133 · Phase 3 · secondary NCT01810380
  • 4.5 vs 7.6 0.25 mg · wk 6 · n 39 · Phase 2 · secondary NCT00905307
  • 11.4 vs 7.6 Low-dose · wk 6 · n 86 · Phase 2 · secondary NCT00905307
  • 10.7 vs 7.6 Mid-dose · wk 6 · n 84 · Phase 2 · secondary NCT00905307
  • 12.2 vs 7.6 High-dose · wk 6 · n 90 · Phase 2 · secondary NCT00905307

Relapse (% of patients)

Aripiprazole (Abilify Maintena)
10% vs 39.6%−29.6 vs placebowk 52 · n 269NCT00705783
Brexpiprazole (Rexulti)
13.5% vs 38.5%−24.9 vs placebowk 52 · n 96NCT01668797
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
11 other shared endpoints and safety

Coverage. Aripiprazole (Abilify Maintena): 15 of 15 rows · Brexpiprazole (Rexulti): 15 of 15 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAripiprazole (Abilify Maintena)
Rows use multiple source trials
Brexpiprazole (Rexulti)
Rows use multiple source trials
CGI-I
absolute value · score
2.7 vs 3.7 placebo score @ 10wk400/300 mga,b,c
NCT01663532 · Phase 3
3.77 vs 4.4 placebo score @ 52wka,b,c
NCT01668797 · Phase 3
CGI-I
absolute value · score
No placebo or comparator arm
3.25 score @ 52wk400/300 mg IM Depota,b,d
NCT00731549 · Phase 3 · registry result, not featured evidence
1.9 scoree,a,b,d
NCT03238326 · Phase 3
show 3 more doses
2.1 score
NCT03238326 · Phase 3
2.1 score
NCT03238326 · Phase 3
2.2 score
NCT03238326 · Phase 3
CGI-S
absolute change · score
No placebo or comparator arm
-0.24 score @ 52wk400/300 mg IM Depota,b
NCT00731549 · Phase 3 · registry result, not featured evidence
-0.48 score @ 52wke,a,b
NCT01397786 · Phase 3 · registry result, not featured evidence
show 2 more doses
-0.55 score @ 52wk
NCT01397786 · Phase 3 · registry result, not featured evidence
-0.97 score @ 52wk
NCT01397786 · Phase 3 · registry result, not featured evidence
PANSS Negative
absolute change · score
No placebo or comparator arm
-0.96 score @ 4wk400mge,f,a,b,g
NCT01552772 · Phase 1 · registry result, not featured evidence
show 1 more dose
-0.92 score @ 4wk400mg
NCT01552772 · Phase 1 · registry result, not featured evidence
-2 score @ 52wke,f,a,b,g
NCT01397786 · Phase 3 · registry result, not featured evidence
show 2 more doses
-2.7 score @ 52wk
NCT01397786 · Phase 3 · registry result, not featured evidence
-3.7 score @ 52wk
NCT01397786 · Phase 3 · registry result, not featured evidence
PANSS Negative Subscale
absolute change · score
-3.5 vs -1.3 placebo score @ 6wk400/300 mga,b
NCT01663532 · Phase 3
-4.02 vs -2.24 placebo score @ 6wk2 mge,a,b
NCT01396421 · Phase 3
show 2 more doses
-3.65 vs -2.24 placebo score @ 6wk4 mg
NCT01396421 · Phase 3
-3.31 vs -2.24 placebo score @ 6wk0.25 mg
NCT01396421 · Phase 3
PANSS Negative Subscale
absolute change · score
No placebo or comparator arm
-0.33 score @ 20wk400 mgf,a,b,d
NCT01909466 · Phase 1 · registry result, not featured evidence
-4.4 scoree,f,a,b,d
NCT03238326 · Phase 3
show 3 more doses
-4.82 score
NCT03238326 · Phase 3
-4.89 score
NCT03238326 · Phase 3
-4.55 score
NCT03238326 · Phase 3
PANSS Positive
absolute change · score
No placebo or comparator arm
-1.28 score @ 4wk400mge,f,a,b,g
NCT01552772 · Phase 1 · registry result, not featured evidence
show 1 more dose
-1.25 score @ 4wk400mg
NCT01552772 · Phase 1 · registry result, not featured evidence
-2.3 score @ 52wke,f,a,b,g
NCT01397786 · Phase 3 · registry result, not featured evidence
show 2 more doses
-3.2 score @ 52wk
NCT01397786 · Phase 3 · registry result, not featured evidence
-5.8 score @ 52wk
NCT01397786 · Phase 3 · registry result, not featured evidence
PANSS Positive Subscale
absolute change · score
-8.2 vs -4.4 placebo score @ 6wk400/300 mga,b
NCT01663532 · Phase 3
-6.57 vs -4.35 placebo score @ 6wk2 mge,a,b
NCT01396421 · Phase 3
show 2 more doses
-6.78 vs -4.35 placebo score @ 6wk4 mg
NCT01396421 · Phase 3
-5.46 vs -4.35 placebo score @ 6wk0.25 mg
NCT01396421 · Phase 3
PANSS Positive Subscale
absolute change · score
No placebo or comparator arm
-0.52 score @ 20wk400 mgf,a,b,d
NCT01909466 · Phase 1 · registry result, not featured evidence
-5.15 scoree,f,a,b,d
NCT03238326 · Phase 3
show 3 more doses
-4.59 score
NCT03238326 · Phase 3
-5.2 score
NCT03238326 · Phase 3
-5.29 score
NCT03238326 · Phase 3
PANSS Total
absolute change · score
No placebo or comparator arm
-3.55 score @ 52wk400/300 mg IM Depota,b,d
NCT00731549 · Phase 3 · registry result, not featured evidence
-19 scoree,a,b,d
NCT03238326 · Phase 3
show 3 more doses
-18.44 score
NCT03238326 · Phase 3
-20.14 score
NCT03238326 · Phase 3
-19.76 score
NCT03238326 · Phase 3
QLS Total
absolute change · score
70.05 vs 62.21 Clinician's Choice score @ 104wka,b,h
NCT02360319 · Phase 4 · registry result, not featured evidence
4.049 vs -5.146 Treatment as Usual score @ 12wka,b,h
NCT03526354 · Phase 4 · registry result, not featured evidence
Dropout rate
—300 or 400 mgi
NCT00706654 · Phase 3
show 13 more results
—25 or 50 mg
NCT00706654 · Phase 3
—Aripiprazole Depot
NCT00705783 · Phase 3 · monotherapy
—Aripiprazole Depot - Depot Mainten
NCT00705783 · Phase 3 · monotherapy
44%400/300 mg
NCT01663532 · Phase 3
26.1%
NCT02360319 · Phase 4 · registry result, not featured evidence
12.5%
NCT01959035 · Phase 3 · registry result, not featured evidence
32.4%
NCT01795547 · Phase 3 · registry result, not featured evidence
39.2%400/300 mg
NCT01683058 · Phase 3 · registry result, not featured evidence
20.6%400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
—400 mg
NCT01909466 · Phase 1 · registry result, not featured evidence
11.1%400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
26.3%400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
6.7%400mg
NCT01552772 · Phase 1 · registry result, not featured evidence
30.6%2 mgi
NCT01393613 · Phase 3
show 45 more results
29.3%4 mg
NCT01393613 · Phase 3
32.5%1 mg
NCT01393613 · Phase 3
—2 mg
NCT01396421 · Phase 3
31.9%2 mg
NCT01396421 · Phase 3
32.8%4 mg
NCT01396421 · Phase 3
—4 mg
NCT01396421 · Phase 3
—0.25 mg
NCT01396421 · Phase 3
37.8%0.25 mg
NCT01396421 · Phase 3
0%De Novo (Conversion Period)
NCT03238326 · Phase 3
—De Novo (OLT Period)
NCT03238326 · Phase 3
—Prior & Current Brexpiprazole (OLT
NCT03238326 · Phase 3
—Prior Aripiprazole & Current Brexp
NCT03238326 · Phase 3
—Prior Placebo & Current Brexpipraz
NCT03238326 · Phase 3
—Prior and Current Brexpiprazole
NCT03238326 · Phase 3
2.7%
NCT03198078 · Phase 3
—
NCT01668797 · Phase 3
28.6%
NCT03526354 · Phase 4 · registry result, not featured evidence
15.8%2 mg
NCT02194933 · Phase 3 · registry result, not featured evidence
47.4%4 mg
NCT02194933 · Phase 3 · registry result, not featured evidence
12.3%De Novo
NCT01397786 · Phase 3 · registry result, not featured evidence
—De Novo (Phase A)
NCT01397786 · Phase 3 · registry result, not featured evidence
—De Novo (Phase B)
NCT01397786 · Phase 3 · registry result, not featured evidence
0%Prior Brexpiprazole
NCT01397786 · Phase 3 · registry result, not featured evidence
—Prior Brexpiprazole (Phase B)
NCT01397786 · Phase 3 · registry result, not featured evidence
—Prior Placebo
NCT01397786 · Phase 3 · registry result, not featured evidence
—Prior Placebo (Phase B)
NCT01397786 · Phase 3 · registry result, not featured evidence
51.9%
NCT01810783 · Phase 3 · registry result, not featured evidence
25.2%
NCT01810380 · Phase 3 · registry result, not featured evidence
49%
NCT02013622 · Phase 3 · registry result, not featured evidence
37.5%
NCT02054702 · Phase 3 · registry result, not featured evidence
29.6%2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
39.8%4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
37.4%1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
52.4%0.25 mg
NCT00905307 · Phase 2 · registry result, not featured evidence
—High-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
41.6%Low-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
41.1%Mid-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
—Fasted Stated
NCT06036108 · Phase 1 · registry result, not featured evidence
—Fed Stated
NCT06036108 · Phase 1 · registry result, not featured evidence
0%4 mg
NCT01854944 · Phase 1 · registry result, not featured evidence
25%4 mg
NCT01854944 · Phase 1 · registry result, not featured evidence
0%1 mg
NCT01854944 · Phase 1 · registry result, not featured evidence
14.9%4 mg
NCT01423916 · Phase 1 · registry result, not featured evidence
27.4%12 mg
NCT01423916 · Phase 1 · registry result, not featured evidence
—3mg
NCT01289080 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—300 or 400 mgi
NCT00706654 · Phase 3
show 13 more results
—25 or 50 mg
NCT00706654 · Phase 3
—Aripiprazole Depot
NCT00705783 · Phase 3 · monotherapy
—Aripiprazole Depot - Depot Mainten
NCT00705783 · Phase 3 · monotherapy
4.2%400/300 mg
NCT01663532 · Phase 3
—
NCT02360319 · Phase 4 · registry result, not featured evidence
5.7%
NCT01959035 · Phase 3 · registry result, not featured evidence
10.8%
NCT01795547 · Phase 3 · registry result, not featured evidence
8.1%400/300 mg
NCT01683058 · Phase 3 · registry result, not featured evidence
2.9%400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
—400 mg
NCT01909466 · Phase 1 · registry result, not featured evidence
—400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
—400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
1.7%400mg
NCT01552772 · Phase 1 · registry result, not featured evidence
5.9%2 mgi
NCT01393613 · Phase 3
show 45 more results
7.1%4 mg
NCT01393613 · Phase 3
9.2%1 mg
NCT01393613 · Phase 3
—2 mg
NCT01396421 · Phase 3
8.2%2 mg
NCT01396421 · Phase 3
9.4%4 mg
NCT01396421 · Phase 3
—4 mg
NCT01396421 · Phase 3
—0.25 mg
NCT01396421 · Phase 3
13.3%0.25 mg
NCT01396421 · Phase 3
—De Novo (Conversion Period)
NCT03238326 · Phase 3
—De Novo (OLT Period)
NCT03238326 · Phase 3
—Prior & Current Brexpiprazole (OLT
NCT03238326 · Phase 3
—Prior Aripiprazole & Current Brexp
NCT03238326 · Phase 3
—Prior Placebo & Current Brexpipraz
NCT03238326 · Phase 3
—Prior and Current Brexpiprazole
NCT03238326 · Phase 3
0%
NCT03198078 · Phase 3
—
NCT01668797 · Phase 3
—
NCT03526354 · Phase 4 · registry result, not featured evidence
—2 mg
NCT02194933 · Phase 3 · registry result, not featured evidence
—4 mg
NCT02194933 · Phase 3 · registry result, not featured evidence
3.5%De Novo
NCT01397786 · Phase 3 · registry result, not featured evidence
—De Novo (Phase A)
NCT01397786 · Phase 3 · registry result, not featured evidence
—De Novo (Phase B)
NCT01397786 · Phase 3 · registry result, not featured evidence
0%Prior Brexpiprazole
NCT01397786 · Phase 3 · registry result, not featured evidence
—Prior Brexpiprazole (Phase B)
NCT01397786 · Phase 3 · registry result, not featured evidence
—Prior Placebo
NCT01397786 · Phase 3 · registry result, not featured evidence
—Prior Placebo (Phase B)
NCT01397786 · Phase 3 · registry result, not featured evidence
15.2%
NCT01810783 · Phase 3 · registry result, not featured evidence
9.3%
NCT01810380 · Phase 3 · registry result, not featured evidence
6.1%
NCT02013622 · Phase 3 · registry result, not featured evidence
4.7%
NCT02054702 · Phase 3 · registry result, not featured evidence
10.4%2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
15.9%4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
16.5%1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
7.1%0.25 mg
NCT00905307 · Phase 2 · registry result, not featured evidence
—High-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
4.5%Low-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
5.6%Mid-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
—Fasted Stated
NCT06036108 · Phase 1 · registry result, not featured evidence
—Fed Stated
NCT06036108 · Phase 1 · registry result, not featured evidence
—4 mg
NCT01854944 · Phase 1 · registry result, not featured evidence
—4 mg
NCT01854944 · Phase 1 · registry result, not featured evidence
—1 mg
NCT01854944 · Phase 1 · registry result, not featured evidence
6.8%4 mg
NCT01423916 · Phase 1 · registry result, not featured evidence
12.3%12 mg
NCT01423916 · Phase 1 · registry result, not featured evidence
—3mg
NCT01289080 · Phase 1 · registry result, not featured evidence
Serious AEs
5.7%300 or 400 mgi
NCT00706654 · Phase 3
show 13 more results
8.4%25 or 50 mg
NCT00706654 · Phase 3
—Aripiprazole Depot
NCT00705783 · Phase 3 · monotherapy
4.1%Aripiprazole Depot - Depot Mainten
NCT00705783 · Phase 3 · monotherapy
4.8%400/300 mg
NCT01663532 · Phase 3
29.1%
NCT02360319 · Phase 4 · registry result, not featured evidence
3.4%
NCT01959035 · Phase 3 · registry result, not featured evidence
8.3%
NCT01795547 · Phase 3 · registry result, not featured evidence
6.8%400/300 mg
NCT01683058 · Phase 3 · registry result, not featured evidence
8.8%400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
2.9%400 mg
NCT01909466 · Phase 1 · registry result, not featured evidence
0%400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
0%400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
1.7%400mg
NCT01552772 · Phase 1 · registry result, not featured evidence
2.2%2 mgi
NCT01393613 · Phase 3
show 45 more results
2.2%4 mg
NCT01393613 · Phase 3
2.5%1 mg
NCT01393613 · Phase 3
2.2%2 mg
NCT01396421 · Phase 3
—2 mg
NCT01396421 · Phase 3
—4 mg
NCT01396421 · Phase 3
1.1%4 mg
NCT01396421 · Phase 3
4.4%0.25 mg
NCT01396421 · Phase 3
—0.25 mg
NCT01396421 · Phase 3
0%De Novo (Conversion Period)
NCT03238326 · Phase 3
5%De Novo (OLT Period)
NCT03238326 · Phase 3
—Prior & Current Brexpiprazole (OLT
NCT03238326 · Phase 3
1.1%Prior Aripiprazole & Current Brexp
NCT03238326 · Phase 3
3.4%Prior Placebo & Current Brexpipraz
NCT03238326 · Phase 3
4.1%Prior and Current Brexpiprazole
NCT03238326 · Phase 3
0.9%
NCT03198078 · Phase 3
3.1%
NCT01668797 · Phase 3
0%
NCT03526354 · Phase 4 · registry result, not featured evidence
0%2 mg
NCT02194933 · Phase 3 · registry result, not featured evidence
0%4 mg
NCT02194933 · Phase 3 · registry result, not featured evidence
—De Novo
NCT01397786 · Phase 3 · registry result, not featured evidence
1.8%De Novo (Phase A)
NCT01397786 · Phase 3 · registry result, not featured evidence
11.2%De Novo (Phase B)
NCT01397786 · Phase 3 · registry result, not featured evidence
—Prior Brexpiprazole
NCT01397786 · Phase 3 · registry result, not featured evidence
14.9%Prior Brexpiprazole (Phase B)
NCT01397786 · Phase 3 · registry result, not featured evidence
—Prior Placebo
NCT01397786 · Phase 3 · registry result, not featured evidence
8.9%Prior Placebo (Phase B)
NCT01397786 · Phase 3 · registry result, not featured evidence
14.8%
NCT01810783 · Phase 3 · registry result, not featured evidence
4.7%
NCT01810380 · Phase 3 · registry result, not featured evidence
0%
NCT02013622 · Phase 3 · registry result, not featured evidence
4.7%
NCT02054702 · Phase 3 · registry result, not featured evidence
4.4%2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
4.4%4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
7%1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
0%0.25 mg
NCT00905307 · Phase 2 · registry result, not featured evidence
4.3%High-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
3.4%Low-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
5.6%Mid-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
0%Fasted Stated
NCT06036108 · Phase 1 · registry result, not featured evidence
1.8%Fed Stated
NCT06036108 · Phase 1 · registry result, not featured evidence
0%4 mg
NCT01854944 · Phase 1 · registry result, not featured evidence
0%4 mg
NCT01854944 · Phase 1 · registry result, not featured evidence
0%1 mg
NCT01854944 · Phase 1 · registry result, not featured evidence
1.4%4 mg
NCT01423916 · Phase 1 · registry result, not featured evidence
0%12 mg
NCT01423916 · Phase 1 · registry result, not featured evidence
0%3mg
NCT01289080 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
300 or 400 mgi
insomnia 11.7%
akathisia 10.6%
headache 9.8%
NCT00706654 · Phase 3
show 12 more results
25 or 50 mg
insomnia 13.7%
back pain 11.5%
weight decreased 9.2%
NCT00706654 · Phase 3
insomnia 10% (placebo 9%)
weight increased 9.7% (placebo 9.7%)
anxiety 5.9% (placebo 7.5%)
NCT00705783 · Phase 3 · monotherapy
400/300 mg
weight increased 16.8% (placebo 7%)
headache 14.4% (placebo 16.3%)
akathisia 11.4% (placebo 3.5%)
NCT01663532 · Phase 3
weight gain 14.4%
anxiety 12.2%
depression 10.4%
NCT02360319 · Phase 4 · registry result, not featured evidence
weight increased 6.8%
NCT01959035 · Phase 3 · registry result, not featured evidence
accidental overdose 20.8%
insomnia 11.8%
weight increased 9%
NCT01795547 · Phase 3 · registry result, not featured evidence
400/300 mg
weight increased 29.7%
akathisia 12.2%
headache 8.1%
NCT01683058 · Phase 3 · registry result, not featured evidence
400/300 mg IM Depot
headache 7.6%
nasopharyngitis 7%
anxiety 6.8%
NCT00731549 · Phase 3 · registry result, not featured evidence
400 mg
injection site pain 27.5%
weight increased 12.3%
headache 11.6%
NCT01909466 · Phase 1 · registry result, not featured evidence
400 mg
injection site pain 35.3%
headache 23.5%
akathisia 17.6%
NCT01646827 · Phase 1 · registry result, not featured evidence
400 mg
injection site pain 27.8%
headache 22.2%
akathisia 16.7%
NCT01646827 · Phase 1 · registry result, not featured evidence
400mg
injection site pain 6.7%
toothache 6.7%
blood creatine phosphokinase increased 5%
NCT01552772 · Phase 1 · registry result, not featured evidence
2 mgi
insomnia 13.4% (placebo 14.7%)
headache 10.8% (placebo 14.7%)
agitation 8.6% (placebo 7.1%)
NCT01393613 · Phase 3
show 38 more results
4 mg
insomnia 15.2% (placebo 14.7%)
headache 10.3% (placebo 14.7%)
agitation 7.1% (placebo 7.1%)
NCT01393613 · Phase 3
1 mg
insomnia 12.5% (placebo 14.7%)
agitation 8.3% (placebo 7.1%)
headache 7.5% (placebo 14.7%)
NCT01393613 · Phase 3
2 mg
headache 9.3% (placebo 8.2%)
insomnia 8.8% (placebo 9.8%)
agitation 6% (placebo 10.3%)
NCT01396421 · Phase 3
4 mg
headache 12.2% (placebo 8.2%)
insomnia 8.3% (placebo 9.8%)
agitation 7.2% (placebo 10.3%)
NCT01396421 · Phase 3
0.25 mg
headache 10% (placebo 8.2%)
insomnia 8.9% (placebo 9.8%)
schizophrenia 6.7% (placebo 9.8%)
NCT01396421 · Phase 3
irritability 14.3%
somnolence 14.3%
akathisia 7.1%
NCT03238326 · Phase 3
somnolence 30%
weight increased 20%
coronavirus test positive 10%
NCT03238326 · Phase 3
weight increased 13.5%
headache 10.1%
somnolence 7.9%
NCT03238326 · Phase 3
headache 12.6%
somnolence 10.3%
weight increased 10.3%
NCT03238326 · Phase 3
headache 10.2%
nasopharyngitis 9.2%
somnolence 9.2%
NCT03238326 · Phase 3
headache 6.4% (placebo 4.8%)
nausea 6.4% (placebo 3.8%)
somnolence 4.5% (placebo 4.8%)
NCT03198078 · Phase 3
agitation 0% (placebo 0%)
akathisia 0% (placebo 0%)
headache 0% (placebo 0%)
NCT01668797 · Phase 3
fatigure/tiredness 14.3%
nausea 14.3%
cold-like symptoms 9.5%
NCT03526354 · Phase 4 · registry result, not featured evidence
2 mg
headache 15.8%
insomnia 10.5%
irritability 10.5%
NCT02194933 · Phase 3 · registry result, not featured evidence
4 mg
agitation 10.5%
anxiety 10.5%
back pain 10.5%
NCT02194933 · Phase 3 · registry result, not featured evidence
agitation 0%
akathisia 0%
headache 0%
NCT01397786 · Phase 3 · registry result, not featured evidence
insomnia 12.5%
headache 9.4%
agitation 9%
NCT01397786 · Phase 3 · registry result, not featured evidence
insomnia 8.4%
weight increased 7.8%
headache 6.9%
NCT01397786 · Phase 3 · registry result, not featured evidence
insomnia 8.4%
weight increased 7.4%
akathisia 6.9%
NCT01397786 · Phase 3 · registry result, not featured evidence
weight increased 10.5%
headache 8.6%
insomnia 8.1%
NCT01810783 · Phase 3 · registry result, not featured evidence
insomnia 8.7% (placebo 6.2%)
akathisia 6% (placebo 2.5%)
headache 5.3% (placebo 6.8%)
NCT01810380 · Phase 3 · registry result, not featured evidence
insomnia 14.3%
somnolence 8.2%
nausea 6.1%
NCT02013622 · Phase 3 · registry result, not featured evidence
akathisia 9.4%
weight increased 9.4%
dry mouth 7.8%
NCT02054702 · Phase 3 · registry result, not featured evidence
2 mg
schizophrenia 11.4% (placebo 24.1%)
headache 7.9% (placebo 4.3%)
constipation 7% (placebo 7.8%)
NCT01451164 · Phase 2/3 · registry result, not featured evidence
4 mg
schizophrenia 20.4% (placebo 24.1%)
nasopharyngitis 8.8% (placebo 9.5%)
vomiting 7.1% (placebo 3.4%)
NCT01451164 · Phase 2/3 · registry result, not featured evidence
1 mg
schizophrenia 17.4% (placebo 24.1%)
nasopharyngitis 10.4% (placebo 9.5%)
constipation 7% (placebo 7.8%)
NCT01451164 · Phase 2/3 · registry result, not featured evidence
0.25 mg
headache 14.3% (placebo 10.5%)
anxiety 11.9% (placebo 10.5%)
agitation 9.5% (placebo 4.2%)
NCT00905307 · Phase 2 · registry result, not featured evidence
High-dose
akathisia 15.1% (placebo 4.2%)
anxiety 10.8% (placebo 10.5%)
insomnia 9.7% (placebo 16.8%)
NCT00905307 · Phase 2 · registry result, not featured evidence
Low-dose
insomnia 13.5% (placebo 16.8%)
headache 9% (placebo 10.5%)
anxiety 7.9% (placebo 10.5%)
NCT00905307 · Phase 2 · registry result, not featured evidence
Mid-dose
headache 14.4% (placebo 10.5%)
insomnia 10% (placebo 16.8%)
weight increased 10% (placebo 3.2%)
NCT00905307 · Phase 2 · registry result, not featured evidence
nausea 9.6%
somnolence 9.6%
diarrhoea 5.8%
NCT06036108 · Phase 1 · registry result, not featured evidence
vomiting 20%
nausea 12.7%
somnolence 12.7%
NCT06036108 · Phase 1 · registry result, not featured evidence
4 mg
abdominal pain 25%
akathisia 25%
blepharospasm 25%
NCT01854944 · Phase 1 · registry result, not featured evidence
4 mg
akathisia 25%
dental carries 25%
dyspepsia 25%
NCT01854944 · Phase 1 · registry result, not featured evidence
1 mg
abdominal discomfort 50%
agitation 25%
abdominal pain 0%
NCT01854944 · Phase 1 · registry result, not featured evidence
4 mg
nausea 10% (placebo 5.9%)
application site dermatitis 8.6% (placebo 5.9%)
dizziness 8.6% (placebo 1.5%)
NCT01423916 · Phase 1 · registry result, not featured evidence
12 mg
dizziness 11.9% (placebo 1.5%)
akathisia 7.5% (placebo 1.5%)
extrapyramidal disorder 7.5% (placebo 1.5%)
NCT01423916 · Phase 1 · registry result, not featured evidence
3mg
somnolence 15.8%
headache 10.5%
orthostatic hypotension 10.5%
NCT01289080 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cAssessment timepoints differ: 52 weeks versus 10 weeks.
  4. dThe assessment timepoint is not available for both results.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fTrial phases differ: Phase 3 versus Phase 1.
  7. gAssessment timepoints differ: 52 weeks versus 4 weeks.
  8. hAssessment timepoints differ: 12 weeks versus 104 weeks.
  9. iPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Aripiprazole (Abilify Maintena)

Exacerbation 7.12% (n=265) @ 26wk300 or 400 mg
absolute value · percentage points
No placebo or comparator arm
NCT00706654 · Phase 3
show 1 more result
21.8% (n=131) @ 26wk25 or 50 mg
NCT00706654 · Phase 3
Time to Exacerbation NA months300 or 400 mg
time to event · months
No placebo or comparator arm
NCT00706654 · Phase 3
show 1 more result
NA months25 or 50 mg
NCT00706654 · Phase 3
Responder 89.8% (n=264) @ 38wk300 or 400 mg
responder rate · % of participants
No placebo or comparator arm
NCT00706654 · Phase 3
show 1 more result
75.2% (n=129) @ 38wk25 or 50 mg
NCT00706654 · Phase 3
Clinical Remission 48.8% (n=215) @ 38wk300 or 400 mg
responder rate · % of participants
No placebo or comparator arm
NCT00706654 · Phase 3
show 1 more result
59.7% (n=72) @ 38wk25 or 50 mg
NCT00706654 · Phase 3
Time to Exacerbation NA vs 6.87 placebo months @ 52wk
time to event · months
Maintenance
NCT00705783 · Phase 3 · monotherapy
PANSS 87.6% (n=267) vs 56% (n=134) placebo @ 52wk
responder rate · % of participants
Maintenance
NCT00705783 · Phase 3 · monotherapy
Clinical Remission 52.9% (n=87) vs 38.7% (n=31) placebo @ 52wk
responder rate · % of participants
Maintenance
NCT00705783 · Phase 3 · monotherapy
PANSS Total 1.43 vs 11.55 placebo score @ 52wk
absolute change · score
Maintenance
NCT00705783 · Phase 3 · monotherapy
CGI-S 0.14 vs 0.66 placebo score @ 52wk
absolute change · score
Maintenance
NCT00705783 · Phase 3 · monotherapy
PANSS Positive Subscale 0.44 vs 4.25 placebo score @ 52wk
absolute change · score
Maintenance
NCT00705783 · Phase 3 · monotherapy
PANSS Negative Subscale 0.19 vs 1.55 placebo score @ 52wk
absolute change · score
Maintenance
NCT00705783 · Phase 3 · monotherapy
CGI-I 3.7 vs 4.53 placebo score @ 52wk
absolute value · score
Maintenance
NCT00705783 · Phase 3 · monotherapy

+ 20 further endpoints in the CSV export.

Brexpiprazole (Rexulti)

PANSS Positive -1.43 vs -1.25 placebo score @ 1wk2 mg
absolute change · score
NCT01393613 · Phase 3
show 35 more results
-2.76 vs -2.56 placebo score @ 2wk2 mg
NCT01393613 · Phase 3
-3.56 vs -3.34 placebo score @ 3wk2 mg
NCT01393613 · Phase 3
-4.35 vs -3.93 placebo score @ 4wk2 mg
NCT01393613 · Phase 3
-4.68 vs -4.33 placebo score @ 5wk2 mg
NCT01393613 · Phase 3
-5.42 vs -4.95 placebo score @ 6wk2 mg
NCT01393613 · Phase 3
-1.31 vs -1.09 placebo score @ 1wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.31 vs -2.25 placebo score @ 2wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-3.21 vs -2.57 placebo score @ 3wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-3.69 vs -2.9 placebo score @ 4wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-4.05 vs -3.26 placebo score @ 5wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-4.32 vs -3.69 placebo score @ 6wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-1.8 vs -1.25 placebo score @ 1wk4 mg
NCT01393613 · Phase 3
-2.93 vs -2.56 placebo score @ 2wk4 mg
NCT01393613 · Phase 3
-4.43 vs -3.34 placebo score @ 3wk4 mg
NCT01393613 · Phase 3
-5.16 vs -3.93 placebo score @ 4wk4 mg
NCT01393613 · Phase 3
-6.04 vs -4.33 placebo score @ 5wk4 mg
NCT01393613 · Phase 3
-6.65 vs -4.95 placebo score @ 6wk4 mg
NCT01393613 · Phase 3
-0.7 vs -1.09 placebo score @ 1wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-1.61 vs -2.25 placebo score @ 2wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.71 vs -2.57 placebo score @ 3wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-3.09 vs -2.9 placebo score @ 4wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.89 vs -3.26 placebo score @ 5wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-3.15 vs -3.69 placebo score @ 6wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-0.93 vs -1.25 placebo score @ 1wk1 mg
NCT01393613 · Phase 3
-2.54 vs -2.56 placebo score @ 2wk1 mg
NCT01393613 · Phase 3
-3.94 vs -3.34 placebo score @ 3wk1 mg
NCT01393613 · Phase 3
-4.83 vs -3.93 placebo score @ 4wk1 mg
NCT01393613 · Phase 3
-4.8 vs -4.33 placebo score @ 5wk1 mg
NCT01393613 · Phase 3
-5.63 vs -4.95 placebo score @ 6wk1 mg
NCT01393613 · Phase 3
-0.96 vs -1.09 placebo score @ 1wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-1.72 vs -2.25 placebo score @ 2wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.07 vs -2.57 placebo score @ 3wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.39 vs -2.9 placebo score @ 4wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.19 vs -3.26 placebo score @ 5wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.22 vs -3.69 placebo score @ 6wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
PANSS Negative -0.52 vs -0.4 placebo score @ 1wk2 mg
absolute change · score
NCT01393613 · Phase 3
show 35 more results
-1.31 vs -0.79 placebo score @ 2wk2 mg
NCT01393613 · Phase 3
-1.8 vs -1.18 placebo score @ 3wk2 mg
NCT01393613 · Phase 3
-2.09 vs -1.67 placebo score @ 4wk2 mg
NCT01393613 · Phase 3
-2.5 vs -1.74 placebo score @ 5wk2 mg
NCT01393613 · Phase 3
-2.91 vs -2.14 placebo score @ 6wk2 mg
NCT01393613 · Phase 3
-0.83 vs -0.59 placebo score @ 1wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-1.46 vs -0.72 placebo score @ 2wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.41 vs -1.14 placebo score @ 3wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.9 vs -0.81 placebo score @ 4wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-3.24 vs -0.85 placebo score @ 5wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-3.48 vs -1.2 placebo score @ 6wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-0.88 vs -0.4 placebo score @ 1wk4 mg
NCT01393613 · Phase 3
-1.42 vs -0.79 placebo score @ 2wk4 mg
NCT01393613 · Phase 3
-2.15 vs -1.18 placebo score @ 3wk4 mg
NCT01393613 · Phase 3
-2.69 vs -1.67 placebo score @ 4wk4 mg
NCT01393613 · Phase 3
-2.82 vs -1.74 placebo score @ 5wk4 mg
NCT01393613 · Phase 3
-3.36 vs -2.14 placebo score @ 6wk4 mg
NCT01393613 · Phase 3
-0.71 vs -0.59 placebo score @ 1wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-1.76 vs -0.72 placebo score @ 2wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.27 vs -1.14 placebo score @ 3wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.94 vs -0.81 placebo score @ 4wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-3.19 vs -0.85 placebo score @ 5wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-3.24 vs -1.2 placebo score @ 6wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-0.31 vs -0.4 placebo score @ 1wk1 mg
NCT01393613 · Phase 3
-1.27 vs -0.79 placebo score @ 2wk1 mg
NCT01393613 · Phase 3
-2.06 vs -1.18 placebo score @ 3wk1 mg
NCT01393613 · Phase 3
-2.56 vs -1.67 placebo score @ 4wk1 mg
NCT01393613 · Phase 3
-2.71 vs -1.74 placebo score @ 5wk1 mg
NCT01393613 · Phase 3
-2.92 vs -2.14 placebo score @ 6wk1 mg
NCT01393613 · Phase 3
-0.54 vs -0.59 placebo score @ 1wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-1.08 vs -0.72 placebo score @ 2wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-1.64 vs -1.14 placebo score @ 3wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.36 vs -0.81 placebo score @ 4wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.31 vs -0.85 placebo score @ 5wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.34 vs -1.2 placebo score @ 6wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
PANSS-EC -0.46 vs -0.48 placebo score @ 1wk2 mg
absolute change · score
NCT01393613 · Phase 3
show 31 more results
-1.31 vs -0.62 placebo score @ 2wk2 mg
NCT01393613 · Phase 3
-1.31 vs -0.82 placebo score @ 3wk2 mg
NCT01393613 · Phase 3
-1.52 vs -1.12 placebo score @ 4wk2 mg
NCT01393613 · Phase 3
-1.48 vs -0.97 placebo score @ 5wk2 mg
NCT01393613 · Phase 3
-1.9 vs -1.47 placebo score @ 6wk2 mg
NCT01393613 · Phase 3
-2.87 vs -1.64 placebo score @ 6wk2 mg
NCT01396421 · Phase 3
-1.01 vs -0.48 placebo score @ 1wk4 mg
NCT01393613 · Phase 3
-1.21 vs -0.62 placebo score @ 2wk4 mg
NCT01393613 · Phase 3
-1.81 vs -0.82 placebo score @ 3wk4 mg
NCT01393613 · Phase 3
-2.12 vs -1.12 placebo score @ 4wk4 mg
NCT01393613 · Phase 3
-2.27 vs -0.97 placebo score @ 5wk4 mg
NCT01393613 · Phase 3
-2.86 vs -1.47 placebo score @ 6wk4 mg
NCT01393613 · Phase 3
-2.75 vs -1.64 placebo score @ 6wk4 mg
NCT01396421 · Phase 3
-0.35 vs -0.48 placebo score @ 1wk1 mg
NCT01393613 · Phase 3
-0.76 vs -0.62 placebo score @ 2wk1 mg
NCT01393613 · Phase 3
-1.21 vs -0.82 placebo score @ 3wk1 mg
NCT01393613 · Phase 3
-1.58 vs -1.12 placebo score @ 4wk1 mg
NCT01393613 · Phase 3
-1.16 vs -0.97 placebo score @ 5wk1 mg
NCT01393613 · Phase 3
-1.94 vs -1.47 placebo score @ 6wk1 mg
NCT01393613 · Phase 3
-1.99 vs -1.64 placebo score @ 6wk0.25 mg
NCT01396421 · Phase 3
0.32 vs 0.74 placebo score @ 6wk
NCT01668797 · Phase 3
0.5 vs 1.16 placebo score @ 12wk
NCT01668797 · Phase 3
-0.06 vs 0.45 placebo score @ 24wk
NCT01668797 · Phase 3
0.1 vs 1.25 placebo score @ 36wk
NCT01668797 · Phase 3
-0.04 vs 1 placebo score @ 52wk
NCT01668797 · Phase 3
0.38 vs 0.81 placebo score @ 6wk
NCT01668797 · Phase 3
0.73 vs 1.36 placebo score @ 12wk
NCT01668797 · Phase 3
0.78 vs 1.86 placebo score @ 24wk
NCT01668797 · Phase 3
0.89 vs 2.23 placebo score @ 36wk
NCT01668797 · Phase 3
0.82 vs 2.35 placebo score @ 52wk
NCT01668797 · Phase 3
-3.3 vs -2.5 placebo score @ 6wk
NCT01810380 · Phase 3 · registry result, not featured evidence
PANSS Marder Positive -1.77 vs -1.3 placebo score @ 1wk2 mg
absolute change · score
NCT01393613 · Phase 3
show 31 more results
-3.1 vs -3.03 placebo score @ 2wk2 mg
NCT01393613 · Phase 3
-4.09 vs -3.78 placebo score @ 3wk2 mg
NCT01393613 · Phase 3
-4.93 vs -4.67 placebo score @ 4wk2 mg
NCT01393613 · Phase 3
-5.35 vs -5.47 placebo score @ 5wk2 mg
NCT01393613 · Phase 3
-6.26 vs -5.91 placebo score @ 6wk2 mg
NCT01393613 · Phase 3
-7.37 vs -4.89 placebo score @ 6wk2 mg
NCT01396421 · Phase 3
-1.75 vs -1.3 placebo score @ 1wk4 mg
NCT01393613 · Phase 3
-3.03 vs -3.03 placebo score @ 2wk4 mg
NCT01393613 · Phase 3
-4.39 vs -3.78 placebo score @ 3wk4 mg
NCT01393613 · Phase 3
-5.48 vs -4.67 placebo score @ 4wk4 mg
NCT01393613 · Phase 3
-6.41 vs -5.47 placebo score @ 5wk4 mg
NCT01393613 · Phase 3
-7.05 vs -5.91 placebo score @ 6wk4 mg
NCT01393613 · Phase 3
-7.23 vs -4.89 placebo score @ 6wk4 mg
NCT01396421 · Phase 3
-1.44 vs -1.3 placebo score @ 1wk1 mg
NCT01393613 · Phase 3
-2.97 vs -3.03 placebo score @ 2wk1 mg
NCT01393613 · Phase 3
-4.48 vs -3.78 placebo score @ 3wk1 mg
NCT01393613 · Phase 3
-5.42 vs -4.67 placebo score @ 4wk1 mg
NCT01393613 · Phase 3
-5.86 vs -5.47 placebo score @ 5wk1 mg
NCT01393613 · Phase 3
-6.56 vs -5.91 placebo score @ 6wk1 mg
NCT01393613 · Phase 3
-5.78 vs -4.89 placebo score @ 6wk0.25 mg
NCT01396421 · Phase 3
-0.1 vs 1.24 placebo score @ 6wk
NCT01668797 · Phase 3
-0.18 vs 1.83 placebo score @ 12wk
NCT01668797 · Phase 3
-0.82 vs 0.77 placebo score @ 24wk
NCT01668797 · Phase 3
-1.35 vs 0.93 placebo score @ 36wk
NCT01668797 · Phase 3
-1.62 vs 1.78 placebo score @ 52wk
NCT01668797 · Phase 3
0.05 vs 1.13 placebo score @ 6wk
NCT01668797 · Phase 3
0.1 vs 2.03 placebo score @ 12wk
NCT01668797 · Phase 3
0.25 vs 3.08 placebo score @ 24wk
NCT01668797 · Phase 3
0.6 vs 3.69 placebo score @ 36wk
NCT01668797 · Phase 3
0.58 vs 4.02 placebo score @ 52wk
NCT01668797 · Phase 3
-7.1 vs -5.7 placebo score @ 6wk
NCT01810380 · Phase 3 · registry result, not featured evidence
PANSS Marder Negative -0.85 vs -0.66 placebo score @ 1wk2 mg
absolute change · score
NCT01393613 · Phase 3
show 31 more results
-1.86 vs -1.38 placebo score @ 2wk2 mg
NCT01393613 · Phase 3
-2.3 vs -1.83 placebo score @ 3wk2 mg
NCT01393613 · Phase 3
-2.63 vs -2.16 placebo score @ 4wk2 mg
NCT01393613 · Phase 3
-3.13 vs -2.24 placebo score @ 5wk2 mg
NCT01393613 · Phase 3
-3.53 vs -2.55 placebo score @ 6wk2 mg
NCT01393613 · Phase 3
-4.48 vs -2.8 placebo score @ 6wk2 mg
NCT01396421 · Phase 3
-1.12 vs -0.66 placebo score @ 1wk4 mg
NCT01393613 · Phase 3
-1.72 vs -1.38 placebo score @ 2wk4 mg
NCT01393613 · Phase 3
-2.64 vs -1.83 placebo score @ 3wk4 mg
NCT01393613 · Phase 3
-3.17 vs -2.16 placebo score @ 4wk4 mg
NCT01393613 · Phase 3
-3.21 vs -2.24 placebo score @ 5wk4 mg
NCT01393613 · Phase 3
-3.84 vs -2.55 placebo score @ 6wk4 mg
NCT01393613 · Phase 3
-4.1 vs -2.8 placebo score @ 6wk4 mg
NCT01396421 · Phase 3
-0.7 vs -0.66 placebo score @ 1wk1 mg
NCT01393613 · Phase 3
-1.71 vs -1.38 placebo score @ 2wk1 mg
NCT01393613 · Phase 3
-2.55 vs -1.83 placebo score @ 3wk1 mg
NCT01393613 · Phase 3
-3.21 vs -2.16 placebo score @ 4wk1 mg
NCT01393613 · Phase 3
-3.35 vs -2.24 placebo score @ 5wk1 mg
NCT01393613 · Phase 3
-3.55 vs -2.55 placebo score @ 6wk1 mg
NCT01393613 · Phase 3
-3.66 vs -2.8 placebo score @ 6wk0.25 mg
NCT01396421 · Phase 3
0.02 vs 0.68 placebo score @ 6wk
NCT01668797 · Phase 3
-0.01 vs 0.8 placebo score @ 12wk
NCT01668797 · Phase 3
-0.71 vs 0.46 placebo score @ 24wk
NCT01668797 · Phase 3
-0.8 vs 0.7 placebo score @ 36wk
NCT01668797 · Phase 3
1.37 vs 1.06 placebo score @ 52wk
NCT01668797 · Phase 3
-0.24 vs 0.61 placebo score @ 6wk
NCT01668797 · Phase 3
-0.15 vs 1.09 placebo score @ 12wk
NCT01668797 · Phase 3
-0.09 vs 1.5 placebo score @ 24wk
NCT01668797 · Phase 3
-0.07 vs 1.56 placebo score @ 36wk
NCT01668797 · Phase 3
0.34 vs 1.57 placebo score @ 52wk
NCT01668797 · Phase 3
-4.3 vs -3.6 placebo score @ 6wk
NCT01810380 · Phase 3 · registry result, not featured evidence
PANSS Marder Disorganized Thought -0.46 vs -0.42 placebo score @ 1wk2 mg
absolute change · score
NCT01393613 · Phase 3
show 28 more results
-1.15 vs -0.71 placebo score @ 2wk2 mg
NCT01393613 · Phase 3
-1.71 vs -1.35 placebo score @ 3wk2 mg
NCT01393613 · Phase 3
-2.27 vs -1.77 placebo score @ 4wk2 mg
NCT01393613 · Phase 3
-2.55 vs -2.01 placebo score @ 5wk2 mg
NCT01393613 · Phase 3
-2.94 vs -2.59 placebo score @ 6wk2 mg
NCT01393613 · Phase 3
-0.78 vs -0.42 placebo score @ 1wk4 mg
NCT01393613 · Phase 3
-1.37 vs -0.71 placebo score @ 2wk4 mg
NCT01393613 · Phase 3
-2.32 vs -1.35 placebo score @ 3wk4 mg
NCT01393613 · Phase 3
-2.83 vs -1.77 placebo score @ 4wk4 mg
NCT01393613 · Phase 3
-3.42 vs -2.01 placebo score @ 5wk4 mg
NCT01393613 · Phase 3
-3.98 vs -2.59 placebo score @ 6wk4 mg
NCT01393613 · Phase 3
-0.4 vs -0.42 placebo score @ 1wk1 mg
NCT01393613 · Phase 3
-1.42 vs -0.71 placebo score @ 2wk1 mg
NCT01393613 · Phase 3
-2.35 vs -1.35 placebo score @ 3wk1 mg
NCT01393613 · Phase 3
-2.56 vs -1.77 placebo score @ 4wk1 mg
NCT01393613 · Phase 3
-2.95 vs -2.01 placebo score @ 5wk1 mg
NCT01393613 · Phase 3
-3.46 vs -2.59 placebo score @ 6wk1 mg
NCT01393613 · Phase 3
-0.18 vs 0.32 placebo score @ 6wk
NCT01668797 · Phase 3
-0.44 vs 0.69 placebo score @ 12wk
NCT01668797 · Phase 3
-1.26 vs 0.27 placebo score @ 24wk
NCT01668797 · Phase 3
-1.31 vs 0.17 placebo score @ 36wk
NCT01668797 · Phase 3
-0.37 vs -0.3 placebo score @ 52wk
NCT01668797 · Phase 3
-0.32 vs 0.33 placebo score @ 6wk
NCT01668797 · Phase 3
-0.19 vs 1.19 placebo score @ 12wk
NCT01668797 · Phase 3
-0.29 vs 1.76 placebo score @ 24wk
NCT01668797 · Phase 3
0 vs 1.95 placebo score @ 36wk
NCT01668797 · Phase 3
0.29 vs 1.97 placebo score @ 52wk
NCT01668797 · Phase 3
-4 vs -3.2 placebo score @ 6wk
NCT01810380 · Phase 3 · registry result, not featured evidence
PANSS Marder Uncontrolled Hostility/Excitement -0.1 vs -0.21 placebo score @ 1wk2 mg
absolute change · score
NCT01393613 · Phase 3
show 31 more results
-0.65 vs -0.13 placebo score @ 2wk2 mg
NCT01393613 · Phase 3
-0.61 vs -0.19 placebo score @ 3wk2 mg
NCT01393613 · Phase 3
-0.74 vs -0.39 placebo score @ 4wk2 mg
NCT01393613 · Phase 3
-0.6 vs -0.22 placebo score @ 5wk2 mg
NCT01393613 · Phase 3
-0.81 vs -0.64 placebo score @ 6wk2 mg
NCT01393613 · Phase 3
-1.91 vs -0.82 placebo score @ 6wk2 mg
NCT01396421 · Phase 3
-0.63 vs -0.21 placebo score @ 1wk4 mg
NCT01393613 · Phase 3
-0.68 vs -0.13 placebo score @ 2wk4 mg
NCT01393613 · Phase 3
-1.16 vs -0.19 placebo score @ 3wk4 mg
NCT01393613 · Phase 3
-1.31 vs -0.39 placebo score @ 4wk4 mg
NCT01393613 · Phase 3
-1.5 vs -0.22 placebo score @ 5wk4 mg
NCT01393613 · Phase 3
-1.89 vs -0.64 placebo score @ 6wk4 mg
NCT01393613 · Phase 3
-1.9 vs -0.82 placebo score @ 6wk4 mg
NCT01396421 · Phase 3
0.03 vs -0.21 placebo score @ 1wk1 mg
NCT01393613 · Phase 3
-0.15 vs -0.13 placebo score @ 2wk1 mg
NCT01393613 · Phase 3
-0.46 vs -0.19 placebo score @ 3wk1 mg
NCT01393613 · Phase 3
-0.74 vs -0.39 placebo score @ 4wk1 mg
NCT01393613 · Phase 3
-0.34 vs -0.22 placebo score @ 5wk1 mg
NCT01393613 · Phase 3
-0.9 vs -0.64 placebo score @ 6wk1 mg
NCT01393613 · Phase 3
-1.15 vs -0.82 placebo score @ 6wk0.25 mg
NCT01396421 · Phase 3
0.19 vs 0.55 placebo score @ 6wk
NCT01668797 · Phase 3
0.33 vs 0.82 placebo score @ 12wk
NCT01668797 · Phase 3
-0.26 vs 0.81 placebo score @ 24wk
NCT01668797 · Phase 3
-0.13 vs 0.94 placebo score @ 36wk
NCT01668797 · Phase 3
-0.2 vs 0.94 placebo score @ 52wk
NCT01668797 · Phase 3
0.32 vs 0.65 placebo score @ 6wk
NCT01668797 · Phase 3
0.52 vs 0.94 placebo score @ 12wk
NCT01668797 · Phase 3
0.5 vs 1.31 placebo score @ 24wk
NCT01668797 · Phase 3
0.57 vs 1.63 placebo score @ 36wk
NCT01668797 · Phase 3
0.49 vs 1.75 placebo score @ 52wk
NCT01668797 · Phase 3
-2.5 vs -1.8 placebo score @ 6wk
NCT01810380 · Phase 3 · registry result, not featured evidence
PANSS Marder Anxiety Depression -1.1 vs -0.96 placebo score @ 1wk2 mg
absolute change · score
NCT01393613 · Phase 3
show 31 more results
-1.91 vs -1.47 placebo score @ 2wk2 mg
NCT01393613 · Phase 3
-2.1 vs -1.97 placebo score @ 3wk2 mg
NCT01393613 · Phase 3
-2.7 vs -2.6 placebo score @ 4wk2 mg
NCT01393613 · Phase 3
-2.87 vs -2.69 placebo score @ 5wk2 mg
NCT01393613 · Phase 3
-3.62 vs -2.93 placebo score @ 6wk2 mg
NCT01393613 · Phase 3
-3.7 vs -3.05 placebo score @ 6wk2 mg
NCT01396421 · Phase 3
-1.26 vs -0.96 placebo score @ 1wk4 mg
NCT01393613 · Phase 3
-1.6 vs -1.47 placebo score @ 2wk4 mg
NCT01393613 · Phase 3
-2.24 vs -1.97 placebo score @ 3wk4 mg
NCT01393613 · Phase 3
-2.93 vs -2.6 placebo score @ 4wk4 mg
NCT01393613 · Phase 3
-3.09 vs -2.69 placebo score @ 5wk4 mg
NCT01393613 · Phase 3
-3.78 vs -2.93 placebo score @ 6wk4 mg
NCT01393613 · Phase 3
-3.4 vs -3.05 placebo score @ 6wk4 mg
NCT01396421 · Phase 3
-1.18 vs -0.96 placebo score @ 1wk1 mg
NCT01393613 · Phase 3
-1.86 vs -1.47 placebo score @ 2wk1 mg
NCT01393613 · Phase 3
-2.43 vs -1.97 placebo score @ 3wk1 mg
NCT01393613 · Phase 3
-2.85 vs -2.6 placebo score @ 4wk1 mg
NCT01393613 · Phase 3
-2.93 vs -2.69 placebo score @ 5wk1 mg
NCT01393613 · Phase 3
-3.57 vs -2.93 placebo score @ 6wk1 mg
NCT01393613 · Phase 3
-3.27 vs -3.05 placebo score @ 6wk0.25 mg
NCT01396421 · Phase 3
0.19 vs 0.66 placebo score @ 6wk
NCT01668797 · Phase 3
0.54 vs 0.78 placebo score @ 12wk
NCT01668797 · Phase 3
0.61 vs 0.58 placebo score @ 24wk
NCT01668797 · Phase 3
0.46 vs 0.71 placebo score @ 36wk
NCT01668797 · Phase 3
0.04 vs 0.28 placebo score @ 52wk
NCT01668797 · Phase 3
0.19 vs 0.85 placebo score @ 6wk
NCT01668797 · Phase 3
0.86 vs 1.41 placebo score @ 12wk
NCT01668797 · Phase 3
1.07 vs 1.64 placebo score @ 24wk
NCT01668797 · Phase 3
1.09 vs 1.79 placebo score @ 36wk
NCT01668797 · Phase 3
1.17 vs 1.88 placebo score @ 52wk
NCT01668797 · Phase 3
-3.2 vs -2.9 placebo score @ 6wk
NCT01810380 · Phase 3 · registry result, not featured evidence
Overall 47.78% (n=180) vs 30.34% (n=178) placebo @ 6wk2 mg
responder rate · % of participants
NCT01396421 · Phase 3
show 3 more results
46.07% (n=178) vs 30.34% (n=178) placebo @ 6wk4 mg
NCT01396421 · Phase 3
39.08% (n=87) vs 30.34% (n=178) placebo @ 6wk0.25 mg
NCT01396421 · Phase 3
60.9% (n=64) vs 48.5% (n=33) Aripiprazole @ 6wk
NCT02054702 · Phase 3 · registry result, not featured evidence
PANSS Marder Disorganised Thought -3.94 vs -1.97 placebo score @ 6wk2 mg
absolute change · score
NCT01396421 · Phase 3
show 2 more results
-3.72 vs -1.97 placebo score @ 6wk4 mg
NCT01396421 · Phase 3
-2.69 vs -1.97 placebo score @ 6wk0.25 mg
NCT01396421 · Phase 3
CGAS 13.58 score
absolute change · score
No placebo or comparator arm
NCT03238326 · Phase 3
show 3 more results
14.31 score
NCT03238326 · Phase 3
12.92 score
NCT03238326 · Phase 3
23.05 score
NCT03238326 · Phase 3
CGI-S -1.09 score
absolute value · score
No placebo or comparator arm
NCT03238326 · Phase 3
show 3 more results
-1.11 score
NCT03238326 · Phase 3
-0.86 score
NCT03238326 · Phase 3
-1.3 score
NCT03238326 · Phase 3

+ 44 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aripiprazole (Abilify Maintena)'s landscape · Brexpiprazole (Rexulti)'s landscape